8-K filing — Co-Diagnostics, Inc. (CODX)
Filed: 2026-09-16 AccNo: 0001493152-26-042854 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Co-Diagnostics (NASDAQ:CODX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Co-Diagnostics Enters Material Transfer Agreement With ReadyGo Diagnostics To Evaluate Sample Preparation Technologies For Co-Dx PCR Platform; Material Transfer Agreement Does Not Obligate Either Party To Enter Into Any Development, Supply, Commercialization Or Other Commercial Arrangement
In August 2026, Co-Diagnostics, Inc. (the "Company") entered into a material transfer agreement with ReadyGo Diagnostics Ltd ("ReadyGo") to evaluate the potential compatibility of certain ReadyGo sample
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.